查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529641

偏头痛药物市场规模、份额、趋势分析报告：按治疗层级、途径、治疗、年龄组、按性别、地区、细分市场预测分類的可用性，2024-2030 年

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 159 Pages | 商品交期: 2-10个工作天内

价格

偏头痛药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球偏头痛药物市场规模预计将达到133.4亿美元，预测期内复合年增长率为11.9%。

该市场主要受到疾病盛行率上升、新治疗方法开发、生活方式改变和荷尔蒙药物等因素的推动。

偏头痛是一种使人衰弱的神经系统疾病，其特征是反覆发作持续三天或更长时间的剧烈头痛。偏头痛随着运动而加剧，并可能妨碍患者进行正常的日常活动。大约三分之一的攻击会影响头部、脸部和颈部的两侧。

过去五年，全球偏头痛药物市场相对停滞，主要由非专利药曲坦类药物和其他仿单标示外药物主导。目前大多数处方药物，无论是用于急性治疗或预防性治疗，疗效都很差且有不良副作用。

安进/诺华的 CGRP mAb Aimovig 和 Teva Pharma 的 Ajovy 的推出是改变偏头痛预防治疗模式的第一步。对于礼来(Eli Lilly)、Alder BioPharma 和Biohaven Pharma 等可能在2019 年进入市场的药品製造商来说，基于CGRP 的疗法都将具有相似的功效和安全性，使它们更加实惠似乎是差异化的关键。

偏头痛药物市场报告亮点

  • 由于疾病盛行率上升、新药上市以及研发活动增加，德国在欧洲市场处于领先地位。
  • 急性偏头痛治疗市场得到了新型药物类别的快速采用的支持，例如 CGRP 受体拮抗剂和地坦药物，目前正在多个 II/III 期试验中积极研究这些药物。
  • Biohaven 的 rimegepant 预计将面临艾尔建 (Allergan) 的 ubrogepant 的竞争，后者在 III 期试验中显示出比 rimegepant 更优越的疗效。
  • 礼来公司的 III 期 5-HT1F促效剂lasmiditan 有望成为曲坦类药物无效患者的新型一线非曲坦类急性治疗药物。
  • 大约 20% 寻求偏头痛预防性治疗的患者对现有的学名药没有反应。针对预防性治疗领域未满足的高需求的几种生技药品和小分子药物正在积极开发中。
  • 早期开发阶段的新标靶药物包括AOBiome Therapeutics的AOB-203（抗菌剂）、Winston Pharma的Dolorac（组胺H1受体拮抗剂）、NeuroAxons的NXN-188（NOS抑制剂和曲普坦组合） 、Biohaven的BHV-3500（gepant） ， ETC。这些新型药物正在针对阵发性和慢性偏头痛的多项 I/II 期试验中进行评估。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章偏头痛药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 偏头痛药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析
    • 目标人口分析

第四章偏头痛药物市场：依治疗方法估算与趋势分析

  • 全球偏头痛药物市场：治疗仪表板
  • 全球偏头痛药物市场：治疗变异分析
  • 按治疗分類的收益
  • 急性
  • 预防

第五章偏头痛药物市场：依治疗层级估计与趋势分析

  • 全球偏头痛药物市场：治疗层级仪表板
  • 全球偏头痛药物市场：治疗层级变异分析
  • 按治疗层级的收益
  • CGRP单株抗体
  • CGRP小分子拮抗剂
  • 乙酰胆碱抑制剂/神经毒素
  • 曲普坦
  • 德坦斯
  • 麦角生物碱
  • NSAIDs
  • 其他的

第六章偏头痛药物市场：依给药途径估计与趋势分析

  • 全球偏头痛药物市场：途径途径仪表板
  • 全球偏头痛药物市场：途径变化分析
  • 途径的收益
  • 口服
  • 注射
  • 其他的

第七章偏头痛药物市场：依年龄组别估计及趋势分析

  • 全球偏头痛药物市场：年龄族群板
  • 全球偏头痛药物市场：年龄层波动分析
  • 按年龄组别分類的收益
  • 儿科的
  • 成人
  • 老年人

第八章偏头痛药物市场：可获得性别性别估计及趋势分析

  • 全球偏头痛药物市场：可用性仪表板
  • 全球偏头痛药物市场：可用性变化分析
  • 可用性 性别收益
  • 处方药
  • 非处方药 (OTC)

第九章偏头痛药物市场：治疗、治疗层级、给药途径、年龄组、可用性性别区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第10章竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • AbbVie Inc.
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Gensco Pharma
    • Impel Pharmaceuticals Inc.
    • Currax Pharmaceuticals LLC.
    • Lundbeck
Product Code: GVR-2-68038-559-5

Migraine Drugs Market Growth & Trends:

The global migraine drugs market size is expected to be valued at USD 13.34 billion by 2030, as per a new report by Grand View Research, Inc., exhibiting an 11.9% CAGR during the forecast period. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Migraine Drugs Market Report Highlights:

  • Germany leads the European market, driven by rising disease prevalence, novel drug launches, and an increase in R&D activities
  • The acute migraine treatment market will be supported by the rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
  • Biohaven's rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
  • Eli Lilly's Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
  • Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
  • Drugs with novel targets in early-phase development include AOBiome Therapeutics' AOB-203 (antibacterial), Winston Pharma's Dolorac (histamine H1 receptor antagonists), NeuroAxons' NXN-188 (a combination of NOS inhibitor and a triptan), and Biohaven's BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Therapeutic Class
    • 1.2.3. Route of Administration
    • 1.2.4. Age Group
    • 1.2.5. Availability
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. Therapeutic Class Outlook
    • 2.2.3. Route of Administration Outlook
    • 2.2.4. Age Group Outlook
    • 2.2.5. Availability Outlook
    • 2.2.6. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Migraine Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of migraines
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Migraine Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Target population analysis

Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Migraine Drugs Market: Treatment Dashboard
  • 4.2. Global Migraine Drugs Market: Treatment Movement Analysis
  • 4.3. Global Migraine Drugs Market by Treatment, Revenue
  • 4.4. Acute
    • 4.4.1. Acute market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Preventive
    • 4.5.1. Preventive market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
  • 5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
  • 5.3. Global Migraine Drugs Market Estimates and Forecasts, By Therapeutic Class, Revenue (USD Million)
  • 5.4. CGRP Monoclonal Antibodies
    • 5.4.1. CGRP monoclonal antibodies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. CGRP Small Molecule Antagonists
    • 5.5.1. CGRP small molecule antagonists market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Acetylcholine Inhibitors/ neurotoxins
    • 5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Triptans
    • 5.7.1. Triptans market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. Ditans
    • 5.8.1. Ditans market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.9. Ergot alkaloids
    • 5.9.1. Ergot alkaloids market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.10. NSAIDs
    • 5.10.1. NSAIDs market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Migraine Drugs Market: Route of Administration Dashboard
  • 6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
  • 6.3. Global Migraine Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis

  • 7.1. Global Migraine Drugs Market: Age Group Dashboard
  • 7.2. Global Migraine Drugs Market: Age Group Movement Analysis
  • 7.3. Global Migraine Drugs Market Estimates and Forecasts by Age Group, Revenue (USD Million)
  • 7.4. Pediatric
    • 7.4.1. Pediatric market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Adult
    • 7.5.1. Adult market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Geriatric
    • 7.6.1. Geriatric market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis

  • 8.1. Global Migraine Drugs Market: Availability Dashboard
  • 8.2. Global Migraine Drugs Market: Availability Movement Analysis
  • 8.3. Global Migraine Drugs Market Estimates and Forecasts, by Availability, Revenue (USD Million)
  • 8.4. Prescription Drugs
    • 8.4.1. Prescription Drugs market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5. Over-the-Counter (OTC) Drugs
    • 8.5.1. Over-the-Counter (OTC) Drugs market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, Route of Administration, Age Groupd and Availability

  • 9.1. Regional Dashboard
  • 9.2. Market Size, & Forecasts Trend Analysis, 2018 - 2030
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. Regulatory framework/ reimbursement structure
      • 9.3.1.3. Competitive scenario
      • 9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework/ reimbursement structure
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework/ reimbursement structure
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. Regulatory framework/ reimbursement structure
      • 9.4.1.3. Competitive scenario
      • 9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework/ reimbursement structure
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework/ reimbursement structure
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework/ reimbursement structure
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework/ reimbursement structure
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.6. Denmark
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework/ reimbursement structure
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.7. Norway
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework/ reimbursement structure
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework/ reimbursement structure
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework/ reimbursement structure
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/ reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/ reimbursement structure
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/ reimbursement structure
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework/ reimbursement structure
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework/ reimbursement structure
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework/ reimbursement structure
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework/ reimbursement structure
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2023
    • 10.3.4. AbbVie Inc.
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Product benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Amgen Inc.
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Product benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Teva Pharmaceutical Industries Ltd.
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Product benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. GSK plc
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Product benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Eli Lilly and Company
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Product benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Pfizer Inc.
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Product benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Bausch Health Companies Inc.
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Product benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Gensco Pharma
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Product benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Impel Pharmaceuticals Inc.
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Product benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Currax Pharmaceuticals LLC.
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Product benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Lundbeck
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Product benchmarking
      • 10.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 5 North America migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 7 North America migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 8 U.S. migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 10 U.S. migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 U.S. migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 12 U.S. migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 13 Canada migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Canada migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 15 Canada migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 17 Canada migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 18 Mexico migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 Mexico migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 20 Mexico migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 Mexico migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 22 Mexico migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 23 Europe migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 24 Europe migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Europe migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 26 Europe migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Europe migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 28 Europe migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 29 Germany migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Germany migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 31 Germany migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 33 Germany migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 34 UK migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 UK migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 36 UK migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 UK migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 38 UK migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 39 France migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 France migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 41 France migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 42 France migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 43 France migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 44 Italy migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 Italy migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 46 Italy migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Italy migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 48 Italy migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 49 Spain migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Spain migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 51 Spain migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Spain migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 53 Spain migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 54 Denmark migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Denmark migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 56 Denmark migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 Denmark migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 58 Denmark migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 59 Sweden migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Sweden migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 61 Sweden migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Sweden migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 63 Sweden migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 64 Norway migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Norway migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 66 Norway migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Norway migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 68 Norway migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 72 Aisa Pacific migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 74 Aisa Pacific migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 75 China migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 China migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 77 China migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 China migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 79 China migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 80 Japan migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 81 Japan migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 82 Japan migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Japan migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 84 Japan migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 85 India migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 India migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 87 India migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 India migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 89 India migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 90 South Korea migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 91 South Korea migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 92 South Korea migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 South Korea migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 94 South Korea migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 95 Australia migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 96 Australia migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 97 Australia migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Australia migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 99 Australia migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 100 Thailand migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 101 Thailand migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 102 Thailand migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 Thailand migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 104 Thailand migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 105 Latin America migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 106 Latin America migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 107 Latin America migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 108 Latin America migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 109 Latin America migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 110 Latin America migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 111 Brazil migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 112 Brazil migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 113 Brazil migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 Brazil migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 115 Brazil migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 116 Argentina migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 117 Argentina migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 118 Argentina migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 Argentina migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 120 Argentina migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 121 MEA migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 122 MEA migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 123 MEA migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 124 MEA migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 125 MEA migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 126 MEA migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 127 South Africa migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 128 South Africa migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 129 South Africa migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 130 South Africa migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 131 South Africa migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 137 UAE migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 138 UAE migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 139 UAE migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 140 UAE migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 141 UAE migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 142 Kuwait migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 143 Kuwait migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 144 Kuwait migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 145 Kuwait migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 146 Kuwait migraine drugs market, by availability, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Migraine Drugs market: market outlook
  • Fig. 14 Migraine Drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Migraine Drugs market driver impact
  • Fig. 18 Migraine Drugs market restraint impact
  • Fig. 19 Migraine Drugs market: Treatment movement analysis
  • Fig. 20 Migraine Drugs market: Treatment outlook and key takeaways
  • Fig. 21 Acute market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Migraine Drugs market: Therapeutic Class movement analysis
  • Fig. 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 25 CGRP monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CGRP small molecule antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Triptans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Ditans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Migraine Drugs market: Route of Administration movement analysis
  • Fig. 34 Migraine Drugs market: Route of Administration outlook and key takeaways
  • Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Migraine Drugs market: Age Group movement analysis
  • Fig. 39 Migraine Drugs market: Age Group outlook and key takeaways
  • Fig. 40 Pediatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Adult market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Geriatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Migraine Drugs market: Availability movement analysis
  • Fig. 44 Migraine Drugs market: Availability outlook and key takeaways
  • Fig. 45 Prescription Drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Global Migraine Drugs market: Regional movement analysis
  • Fig. 48 Global Migraine Drugs market: Regional outlook and key takeaways
  • Fig. 49 Global Migraine Drugs market share and leading players
  • Fig. 50 North America, by country
  • Fig. 51 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. key country dynamics
  • Fig. 53 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Canada key country dynamics
  • Fig. 55 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico key country dynamics
  • Fig. 57 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 UK key country dynamics
  • Fig. 60 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Germany key country dynamics
  • Fig. 62 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 France key country dynamics
  • Fig. 64 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Italy key country dynamics
  • Fig. 66 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Spain key country dynamics
  • Fig. 68 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Denmark key country dynamics
  • Fig. 70 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Sweden key country dynamics
  • Fig. 72 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Norway key country dynamics
  • Fig. 74 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 China key country dynamics
  • Fig. 77 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Japan key country dynamics
  • Fig. 79 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 India key country dynamics
  • Fig. 81 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Thailand key country dynamics
  • Fig. 83 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Korea key country dynamics
  • Fig. 85 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Australia key country dynamics
  • Fig. 87 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Brazil key country dynamics
  • Fig. 90 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Argentina key country dynamics
  • Fig. 92 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 South Africa key country dynamics
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Saudi Arabia key country dynamics
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 UAE key country dynamics
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Kuwait key country dynamics
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Market share of key market players- Migraine Drugs market